Medco licenses new radiopharmaceutical

Article

Drug developer Medco Research has acquired a new technetium-basedcardiac radiopharmaceutical, the Research Triangle Park, NC, companyannounced last week. Medco acquired the agent through a licensingdeal with the product's developer, Molecular Targeting

Drug developer Medco Research has acquired a new technetium-basedcardiac radiopharmaceutical, the Research Triangle Park, NC, companyannounced last week. Medco acquired the agent through a licensingdeal with the product's developer, Molecular Targeting Technologyof Malvern, PA. The drug, called technetium-99m Glucarate, isdesigned for the early diagnosis of acute myocardial infarctionand is in phase-I clinical trials.

Medco will have exclusive worldwide rights to develop, manufactureand market the agent. Molecular Targeting will retain rights inAsia, with the exception of Japan.

Another Medco cardiac imaging agent, ViaScint, has completedphase-III trials and the company is planning to file a new drugapplication shortly. ViaScint is designed to help predict whichpatients will have improvement in cardiac function following revascularization.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.